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A common variant of the latrophilin 3 gene, LPHN3, confers
susceptibility to ADHD and predicts effectiveness of stimulant
medication
Abstract
Attention-Deficit/Hyperactivity Disorder (ADHD) has a very high heritability (0.8), suggesting that
about 80% of phenotypic variance is due to genetic factors. We used the integration of statistical and
functional approaches to discover a novel gene that contributes to ADHD. For our statistical approach,
we started with a linkage study based on large multigenerational families in a population isolate,
followed by fine mapping of targeted regions using a family-based design. Family- and
population-based association studies in five samples from disparate regions of the world were used for
replication. Brain imaging studies were performed to evaluate gene function. The linkage study
discovered a genome region harbored in the Latrophilin 3 gene (LPHN3). In the world-wide samples
(total n=6360, with 2627 ADHD cases and 2531 controls) statistical association of LPHN3 and ADHD
was confirmed. Functional studies revealed that LPHN3 variants are expressed in key brain regions
related to attention and activity, affect metabolism in neural circuits implicated in ADHD, and are
associated with response to stimulant medication. Linkage and replicated association of ADHD with a
novel non-candidate gene (LPHN3) provide new insights into the genetics, neurobiology, and treatment
of ADHD.
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ABSTRACT
Attention Deficit Hyperactivity Disorder (ADHD) has a very high heritability (0.8), suggesting about 
80% of phenotypic variance is due to genetic factors.  We used the integration of statistical and 
functional approaches to discover a novel gene that contributes to ADHD.  For our statistical approach, 
we started with a linkage study based on large multigenerational families in a population isolate, 
followed fine mapping of targeted regions based on a family-based design. Family-based and 
population-based association studies in five samples from disparate regions of the world were used for 
replication.  Brain imaging studies were performed to evaluate gene function. The linkage study 
discovered a genome region harbored in the Latrophilin 3 gene (LPHN3). In the world-wide samples 
(total n=6360, with 2627 ADHD cases and 2531 controls) statistical association of LPHN3 and ADHD 
was confirmed. Functional studies revealed that LPHN3 variants are expressed in key brain regions 
related to attention and activity, affect metabolism in neural circuits implicated in ADHD, and are 
associated with response to stimulant medication. Linkage and replicated association of ADHD with a 
novel non-candidate gene (LPHN3) provide new insights into the genetics, neurobiology and treatment
of ADHD.
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Introduction.
Attention-Deficit/Hyperactivity Disorder (ADHD) is the most common behavioral disorder of 
childhood, with a high prevalence1, poor outcome2, substantial costs3, and comorbidity with other 
behavioral and emotional disorders4. Genetic factors are strongly implicated in the etiology of ADHD5.
More than a decade ago, candidate gene association studies identified two genes with small effects6, 7,
and these associations have been replicated8.  Many additional candidate genes have been evaluated, and 
some initial reports of association with ADHD have emerged, but these have not been replicated9.
Several unbiased genome wide studies have been conducted and reported, but none has identified 
additional genes that contribute to the genetic basis of ADHD.  Following the suggestion of Risch and 
Merikangas10, the genome-wide association study (GWAS) approach has been used, but this did not 
produce a significant effect or even confirmed the replicated associations with the DRD4 and DAT 
genes11.
The lack of success of GWA studies to discover new genes related to ADHD is not unexpected.  
As for others disorders and traits with high heritability (such as height), the identified associated genes 
account for 5% to 10% of the estimated heritability, creating a mystery of “dark” or unexplained 
heritability12. It has been assumed that many additional genes with small independent effects likely exist 
but have not been discovered.  The integration of statistical and functional approaches has been 
recommended to uncover the “dark matter” and start to account for the heritability of common 
disorders13.
We identified a large and multigenerational families from a genetic isolate, the Paisa population 
in Antioquia Colombia4, 14.  The prevalence of ADHD is high and often comorbid with disruptive 
behaviors in the Paisa4.  This makes the Paisa population well-suited for a linkage study to discover new 
genes that contribute to the etiology of ADHD.  The initial study in our program of research evaluated 
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ADHD symptoms in informative families ascertained in the Paisa and concluded there would provide 
exceptionally good power to detect linkage even in the presence of heterogeneity15.  A genome wide 
linkage study14 of 16 informative families with 435 individuals reported significant linkage of ADHD to 
a region on chromosome 4q13.214, 16. Fine mapping applied to nine linked families sharpened the linkage 
signal, disclosed new meiotic recombination events in ADHD affected individuals, and in conjunction 
with the LOD-1 support interval criterion narrowed the minimal critical region down to ~20Mb (Table 
1, supplementary information)14. Here we report the next steps in this research program, which were 
designed to identify the gene responsible for the ADHD linkage signal and to elucidate its functional 
properties.
Material and Methods
Subjects
Detailed descriptions of clinical and demographic features of the Paisa sample for the linkage study have
been published elsewhere4.  We used 18 extended families with 433 individuals, and 137 nuclear 
families with 527 individuals.  The samples used for replication were ascertained from disparate regions 
of the world, namely from the US (two independent samples, US117, and US218), Germany19, Norway20,
and Spain21 (see Table 1). A total of 1410 families with 6360 individuals were evaluated.  Approvals to 
conduct the study (Protocol # 00-HG-0058) were obtained from the Institutional Review Boards of the 
National Human Genome Research Institute and those of the collaborating institutions.
Genotyping. 
DNA from the Colombian, US1, US2, German, and Spain samples was prepared from peripheral-blood 
specimens. DNA from the Norway sample was extracted either from whole blood or from saliva. The 
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Illumina genotyping service was used for genotyping, except for the sample from Norway that was
genotyped using Sequenom’s MassARRAY iPLEX System (additional information in supplementary 
information).
Screening of the minimal critical region in 4q13.2
Fine scale mapping with a resolution of ~68kb (a third of the minimum distance able to provide full 
coverage in the Paisa population22) was conducted in the Paisa multigenerational sample of 18 families 
(433 individuals) and in the sample of ADHD 137 nuclear families (527 individuals) ascertained from 
the same genetic isolate. Areas of interest that are gene rich or carry potential candidates were covered at 
a higher density (Figure 1, supplementary information). An empirical linkage disequilibrium map, built 
from control individuals, demonstrated full coverage of the entire region and excluded uncovered gaps 
(Figure 2, supplementary information). 
Screening for sequence variations and SNP tagging
The finding that a shared ADHD susceptibility haplotype was embedded within the LPHN3 gene, and 
the absence of other known genes in the region, prompted further pursuit of the relationship between 
LPHN3 variants and susceptibility to ADHD. Hence, the entire coding region of LPHN3 was sequenced 
in eight individuals carrying two (n=4), one (n=2), or zero (n=2) copies of the susceptibility haplotype 
variants. In addition, 46 individuals from different families showing either nominal, suggestive, or 
significant signals of linkage at the region were also sequenced using SurveyorTM (Transgenomics).
Furthermore, 139 unrelated patients diagnosed with ADHD from the US and 52 commercially-available 
normal controls were also studied. For the US and control samples, mutation detection was performed 
by PCR-based denaturing High Performance Liquid Chromatography (dHPLC) analysis followed by 
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direct bi-directional sequencing (variants identified are presented in Figure 3A, supplementary 
information). Additional SNP selection and tagging employed a quality-based filter, a second population 
information-based filter (MAF, linkage disequilibrium blocks), and a third biological significance-based 
filter (coding, expression modulating, splicing modulating, and assessing evolutionary conservation) 
(Figures 3B-E, supplementary information). Databases used for the selection were SNPdb (NCBI) and 
UCSC genome browser. Quality filtering was based on the information available through the SNP track 
of the UCSC genome browser and by using AB SNPbrowser 3.0. Customized LD blocks were defined 
using AB SNPbrowser 3.0 and Haploview. Biologic relevance was annotated on the UCSC genome 
browser with data available from UCSC (genome browser), NCBI (Entrez), and EBI (Ensembl). 
Conservation was based on the MAF 8X conservation track (courtesy of Elliott Margulies, NHGRI, 
NIH) and Exact Plus software (courtesy of Anthony Antonellis, NHGRI, NIH). The US1, the German 
and the Paisa sample were genotyped for the same set of SNPs (n = 120) (Figure 3E and Table 5, 
supplementary information). The sample from Norway was genotyped using a two-stage design: 60 
markers were first genotyped in 343 adult Norwegian ADHD patients and 336 controls (Table 5, of 
supplementary information). All SNPs with a nominal p-value < 0.15 (7 markers) were then included in 
a second round of genotyping using a new set of 107 cases and 249 controls. The US2 sample was 
genotyped for 77 SNP markers, and the Spanish sample was genotyped for 45 SNP markers (Table 5, 
supplementary information).
Genetic Statistical Analyses 
Family-based association tests were applied by comparing allele frequencies for transmitted and 
untransmitted alleles using PLINK23. Parameters for excluding markers from analyses include a MAF 
less than or equal to 0.05, Hardy-Weinberg equilibrium deviations with p-values <0.0001, and a 
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minimum genotype of 90%. Mendelian errors were checked using PEDSTATS 24. Families with 
excessive Mendelian errors were excluded. SNPs with >2 Mendelian errors also were excluded. We 
tested unaffected siblings looking for overtransmission bias caused by evolutionary forces, such as 
selection in utero against deleterious mutations, meiotic drive, and maternal-fetal incompatibility 25, but 
found no significant overtransmission for any single marker or for any haplotype in the entire region.
Linkage disequilibrium via cladistic analysis was performed using CLADH26 with a Bonferroni-adjusted 
threshold global permutation p-value(10,000 permutations). With CLADH 26, clades of haplotypes are 
tested for association with disease, exploiting the expected similarity of chromosomes with recent shared 
ancestry in the regions flanking the disease gene. We selected only one affected case from each pedigree. 
As controls, haplotypes of unrelated individuals without ADHD were chosen. In order to abrogate 
confounding from potentially undetected genotyping errors and the presence of meiotic drift when the 
risk variants are the most common, we tested additional SNP markers harbored in the LPHN3 gene, 
including those new variants disclosed by our sequencing analyses plus other potentially functional and 
phylogenetically conserved SNP variants (Figures 3A-E, in supplementary information). For haplotype 
analyses both uncertain and infrequent variants (<1%) were excluded from analyses.  To infer genotypes 
not assessed homogeneously in the samples, we performed in silico genotyping as implemented in 
IMPUTE27. The Hapmap CEPH sample was used as our comparison set of phased haplotypes.  All
genotypes inferred with >90% genotype probability were retained. Odds ratios in family based samples
were estimated by the number of transmitted target alleles/the number of untransmitted alleles in 
heterozygous parents only28.  Family-based odds ratios from the TDT tests in the Paisa, US1, US2, 
German, Spanish samples were combined with the case-control odds ratio from the Norwegian using a 
meta-analytical approach29.  The random-effects method30 was used when significant heterogeneity was 
present and the fixed-effects method otherwise31.
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Expression of LPHN3 in human brain. 
We studied the expression of identified genes in northern blots (Human Brain MTN Blots II and V) 
purchased from BD Biosciences (Palo Alto, CA) with the gene probe synthesized based upon its cDNA 
sequence at Invitrogen (Carlsbad, CA) and analyzed in brain tissues from amygdala, caudate nucleus, 
cerebellum, orbital frontal cortex, pontine nuclei, cingulate gyrus, occipital cortex, and thalamus from 
male accident victims deceased at 2, 5, 8 and 30 years of age. 	

	-32P-ATP (GE 
Healthcare, North Arlington Heights, IL) by T4 polynucleotide kinase (Invitrogen) and purified by 
Qiaquick Nucleotide Removal Kit (Qiagen, Valencia, CA). Membranes were prehybridized with 
ExpressHyb (BD Biosciences) for 1 hour (h) at 42 ºC and hybridized with labeled probes for 3 h at 42 
ºC. After hybridization, membranes were stringently washed and exposed on Kodak film at -70ºC for 10 
days. Human brain tissue for in situ hybridization was obtained from the Brain and Tissue Bank for 
Developmental Disorders at the University of Maryland, Baltimore, Maryland from male accident 
victims deceased at 2, 5, 8 and 30 years of age. Though reported as healthy normal individuals, there 
was not information regarding the mental health status. 
A ß-actin probe was used for normalization. The antisense probe for LPHN3, a 362-bp amplicon within 
the final coding exon, was subcloned into Bluescript KS- (Stragene, San Diego, CA) and synthesized 
using a T3 primer. Expression in fetal brain was more pronounced than in whole postnatal brain. 
Fibroblasts and testes also showed notable expression. Minimal expression was detected in thymus, 
lung, prostate, ovaries, heart, pancreas, liver, and kidney. No expression could be detected in cDNAs 
from leucocytes, spleen, skeletal muscle, colon, small intestine, and placenta (data not shown). The in 
situ hybridization experiments were performed at Histoserv, Inc. (Germantown, MD). In addition, a 
panel of normal human pooled cDNAs (BD Biosciences–Clontech, CA, USA) revealed robust 
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expression of a single 3.7 Kb LPHN3 amplicon (primers covering the entire open reading frame) in 
cerebellum, cerebral cortex, thalamus, amygdala, substantia nigra, hippocampus, spinal cord, and retina 
(data not shown). For immunohistochemical analyses serial sections were taken from paraffin embedded 
tissue blocks for immunohistochemical examinations. For antigen retrieval, sections were treated with 
0.01M sodium citrate buffer (pH 6.0) at 100 oC for 10 minutes (min). Sections were cooled at room 
temperature for 20 min and washed three times in PBS. Sections were then quenched for 20 min in a 
solution of 3 ml H2O2 and 180 ml methanol. After three washes in PBS, sections were incubated in 10% 
horse serum for 1h. The LPHN3 primary antibody (1:500, Novus Biologicals, Littleton, CO) was diluted 
in 2% horse serum, and the sections were incubated in a humidified chamber at 4o C overnight. The 
sections were incubated with secondary antibody for 1h followed by avidin-biotin-complex incubation 
for 1h and visualization with diaminobenzidine (DAB). The sections were counterstained with Mayer's 
hematoxylin for 10 min, dehydrated by graded ethanol washes of 95% and 100%, and rinsed in xylene 
before being mounted.
Proton Magnetic Resonance Spectroscopy (1H-MRS) 
We explored potential differences between carriers and noncarriers of the susceptibility haplotype with 
proton magnetic resonance spectroscopy (1H-MRS) to measure neuronal number or viability32 as
assessed by the ratio of N-acetylaspartate (NAA) to creatine (Cr).  Brain regions that define the frontal-
striatal-cerebellar circuit known to be dysfunctional in ADHD33-36 were targeted. To obtain measures of 
metabolic brain activity using 1H-MRS, T2-weighted high resolution anatomic images were obtained in 
the axial plane (TE=103 ms, TR=5910 ms, 3 mm slice thickness, and 5:27 min:seconds imaging time). 
Axial images were oriented parallel to the orbitomeatal anatomical reference plane. The T2-weighted 
images were used to guide multi-voxel MR spectroscopy volume selection. The 2D chemical shift 
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imaging (CSI) point-resolved spectroscopic sequence (PRESS) technique (TE = 30 ms, TR = 1500 ms, 
NEX = 3, resolution 10mm x 10mm x 10mm, acquisition time = 6:05) was localized in the inferior 
vermis using the anatomical reference images. Three-dimensional CSI PRESS sequence (TE = 30 ms, 
TR = 1500 ms, NEX = 3, resolution 13.3 mm x 13.3 mm x 13.8mm, acquisition time = 10:23) explored 
the center of the brain including the striatum, thalamus, and the cingulate gyrus relative to anatomic 
images. Saturation bands around the 2D and 3D Volumes of Interest (VOI) were used to prevent 
contamination of the spectra from subcutaneous fat signal. All MR data were obtained on a 1.5 T 
Symphony Master Class Siemens Clinical Imaging System using an 8 channel head array coil. The 
spectra were transferred off-line to be processed automatically using the LCModel 37. For this initial 
analysis, we focused on the ratio NAA to Cr within each spectral voxel 38. Average data from voxels 
covering the left and right striatum (3-4 voxels), lateral (2 voxels) and medial (2 voxels) aspects of the 
thalamus, anterior (1 voxel), medial (1 voxel) and posterior (1 voxel) cingulate gyrus, and inferior 
vermis (2 voxels) were analyzed. Voxels containing cerebrospinal fluid were excluded from analyses. 
Criteria for acceptable reliability were those recommended by the LCModel provider. The imaged 
participants were neither sedated nor receiving medications for treatment of ADHD. Total scanning 
duration was 45 min. Absolute metabolite quantification was not attempted because of the requirement 
for markedly increased data acquisition time, which is particularly problematic for patients with ADHD.
The general linear model was used to provide exploratory analyses to evaluate between-group 
differences with an uncorrected two-tailed alpha level of 0.05..
Pharmacogenetic Study
An effectiveness evaluation was conducted of medication response in 240 children from the US1 
sample17 rated on and off of stimulant medication on the Strengths and Weaknesses of ADHD-
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Symptoms and Normal-Behavior (SWAN) scale39. By truncating the SWAN ratings, the standard ratings 
of symptom severity (just weaknesses) can be captured. The SWAN scale differs from other scales in its 
definition of items and in its scoring system, which give a closer approximation to a normal distribution 
for each item and of summary scores of overall ADHD and its two domains (Inattention and 
Hyperactivity-Impulsivity) in the general population than does any other ADHD scale that evaluates 
psychopathology 39. In addition, the heritability of the SWAN scale has been demonstrated 39.
Consistency scores were estimated for each interview, using a scale from 1 (unreliable) to 10 (fully 
reliable), according to the concordance between two questions. A full description of ascertainment and 
clinical diagnostic strategies of the US1 sample is presented elsewhere 17.
We used statistical methods to identify clusters to define responders and non-responders using Latent 
Classes Cluster Analysis (LCCA) 40. Latent Class Cluster Analysis (LCCA) models containing one 
through twelve classes were fitted to the data using Latent GOLD 3.0.1 software (Statistical Innovations, 
Belmont, MA). Latent GOLD uses both Expectation/Maximization (EM) and Newton-Raphson 
algorithms to find the maximum likelihood of each model after estimating model parameters 40-42. To 
avoid ending up with local solutions (a well-known problem in LCA), we used multiple sets of starting 
values as automatically implemented in Latent GOLD. Because we were dealing with sparse 
contingency tables, we estimated p-values associated with L2 statistics by means of parametric bootstrap 
(500 replicates) rather than relying on asymptotic p-values. As covariates for the model, we used gender, 
ADHD medication usage and age. Age was included in our models as a continuous variable, as a 
categorical variable based on deciles (i.e., 1-10, 10-20, etc.), and as a categorical variable using the age 
ranges we used previously (i.e., children are between 4 and 11 years; adolescents 12-17; and adults are 
18 years or older)17. Our final models used the latter approach since it resulted in smaller bivariate 
residuals, as described further below.
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Initially, we did not consider the presence of interactions between variables and the basic assumption of 
local independence of the standard latent class model was supported. Next, we relaxed the local 
independence assumption by allowing for interactions between variables, as well as for direct effects of 
covariates on variables 40, 42, 43. Latent GOLD calculates bivariate variable-variable and variable-
covariate residuals that can be used to detect which pairs of observed variables are more strongly 
related. Therefore, bivariate residuals greater than 3.84 were included iteratively for each model to 
identify significant correlations between the associated variable-variable and variable-covariate pairs 
inside each class (for one degree of freedom, bivariate residuals greater than 3.84 indicate statistical 
significance at the 0.05 level). As implemented in Latent GOLD, individuals are assigned posterior 
membership probabilities for belonging to each cluster based on their symptom profiles.  Cases are then 
assigned to the cluster for which the posterior membership probability is highest.  Based on this 
assignment, we compared cluster membership to our DSM-IV-based best-estimate clinical diagnoses of 
ADHD. Effects of covariates like dose, gender and age were controlled. We formed clusters based on 
two procedures. First, we used the traditional procedure based on ratings from just the OFF medication 
condition, which generated 7 cluster (subgroups). Then, we re-established clusters based on parent 
ratings from the ON medication condition, which identified 6 clusters. Then, by estimating conditional 
LCC probabilities of transition, we were able to define probabilities of effectiveness of stimulant 
treatment in ADHD. Significance of the transition between clusters was empirically obtained using 
100,000 simulations assuming the multinomial distribution. Second, we used parent ratings from both 
the ON and OFF medication conditions to establish clusters. Based on these two approaches we 
designated each cluster of ADHD patients to being either responder or not responder to stimulant 
treatment.
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The response trait was tested for association to the candidate SNPs using the TDT. Frequencies and 
proportions were estimated for categorical variables. Means and standard deviations were calculated for 
continuous variables. Categorical variables were compared using the chi-square test. Continuous 
variables fitting both normality and homogeneity of variances were compared using the t-test for 
independent samples; otherwise they were tested using the non-parametric Mann-Whitney’s U test. 
Normality and variance homogeneity were tested with the Shapiro-Wilks and the Bartlett tests, 
respectively. Cohen’s d effect size of not-overlapped data was estimated for all variables using pooled 
variances.
Results
Gene Discovery
The next stage of the positional cloning method of our research program was based on the analysis of 
fine mapping. Partitioned and joint family-based association44, marker45, and haplotype-based26 analyses 
revealed after correction by multiple comparisons a significant area of association with ADHD, 
delimited by the SNP markers rs1901223 and rs1355368 (p=3.1*10-3, marker based; p=2.7*10-5,
haplotype based) (Figure 1A) (Tables 2, 3, & 4, supplementary information). The region of association 
is located at 62.4-62.7 Mb (UCSC coordinates) within the LPHN3 gene encompassing exons 4 through 
19 (Figure 1B). Empirical analysis of meiotic events in ADHD-affected subjects from linked families 
pointed to the same LPHN3 gene region (Figure 1C). The ADHD region of association involves 
sequences coding for the olfactomedin, hormone receptor (HR), the G-protein coupled receptor 
proteolytic site (GPS), and transmembrane domains of LPHN3 (Figure 1D), and contains the bulk of the 
variability conferred by LPHN3 splice isoforms (Figure 1B).
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Figure 2A shows three markers that passed a test of heterogeneity and were significant after adjusting 
for multiple tests: rs6551665 (OR=1.23, 95% CI 1.09-1.37, p=3.46x10-4), rs1947274 (OR=1.23, 95% CI 
1.09-1.38, p=5.41x10-4), rs2345039 (OR=1.21, 95% CI 1.08-1.35, p=8.97 x10-4)(Table 2, Figure 2B). 
Marker rs6551665 was genotyped in all the samples.  In the Hapmap CEPH sample, the Paisa, and the 
US1 sample, these three markers belong to a common LD block. Despite our conservative approach the 
correction of statistical significance due to multiple testing for this gene, p-values reported here have 
strongly overcome estimated threshold values.  
Screening for sequence variations
We sequenced all LPHN3 exons and inton-exon boundaries and identified two SNPs of potential 
significance for the expression profile of LPHN3. Both SNPs are in the haplotype block associated with 
ADHD and are located at splice sites. One SNP, rs1397548 (G>A; major allele in Caucasians: G), is 
located at the last base of the last codon of exon 15. Even though this base change itself does not change 
the translation (synonymous change, i.e., p.P937P), it may affect proper splicing. This splice site variant 
decreases the splice site score from 93 to 80, suggesting a decrease of the recognition of this altered 
splice site leading to a skipping of exon 15 46. The deletion of exon 15, containing 210 bases, is an in 
frame-deletion and would generate a shortened protein with potentially altered functions. The other 
SNP, rs2305339 (A>G; major allele in all populations studied so far: A), is located at the -4 position of 
intron 10. Sequence variations at this position could also cause aberrant splicing, but are less well-
defined. Regular splicing and some aberrant splicing can be the consequence, with generation of a 
regular full length product and potentially an mRNA with a deletion of exon 11. A deletion of exon 11, 
containing 184 bases, is out of frame and would create a premature stop codon at amino acid position 
643. Thus, this variant could generate a certain degree of haploinsufficiency, but importantly it does not 
Arcos-Burgos et al., LPHN3 and ADHD
-17-
predict a complete loss of function for this protein. While preliminary, corroborating the functional 
effect of these variants will require additional studies.
Expression of LPHN3
Northern blot analysis showed significant expression of LPHN3 mRNA in amygdala, caudate nucleus, 
cerebellum, and cerebral cortex (Figure 3A, lanes 1, 2, 7, 8). Lower expression was detected in corpus 
callosum, hippocampus, whole brain extract, occipital pole, frontal lobe, temporal lobe, and putamen 
(Figure 3A, lanes 3, 4, 5, 11, 12, 13, 14). No expression was detected in thalamus, medulla, and spinal 
cord (Figure 3A, lanes 6, 9, 10). LPHN3 expression examined by in situ hybridization of formalin-fixed 
tissues of brain regions from humans of different ages demonstrated a strong cytoplasmic signal in 
neurons of the amygdala, caudate nucleus, pontine nucleus and, in Purkinje cells of the cerebellum at all 
ages tested, i.e., at 2, 5, 8 and 30 years; tissues of a 2-year old are shown in Figure 3B. Involvement of 
the prefrontal cortex, cerebellum, amygdala47, and temporal lobes has been implicated in ADHD48.
Weak cytoplasmic signals for LPHN3 were observed in a subset of cingulate gyrus neurons in the 2- and 
5-year olds, but not in the 8- and 30-year olds, and in indusium griseum neurons in the 2-year old (data 
not shown). Areas of the brain that revealed LPHN3 expression by in situ hybridization were also 
consistently immunoreactive using anti-LPHN3 antibody (Figure 3C).
Brain Chemistry
For 1H-MRS we chose target regions (striatum, cingulated gyrus, and cerebellar vermis) based on prior 
evidence of anatomic abnormalities and added a region that has been difficult to quantify volumetrically
(the medial and lateral thalamus48).  The voxel placement is shown in Figure 4A. MRD was performed 
on a total of 33 individuals selected to differ on the haplotype defines by variants of SNPs rs6551665, 
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rs1947274, and rs2345039, with 15 individuals (ADHD-affected=13, ADHD-unaffected=2) having the
risk haplotype, 10 individuals (ADHD-affected=1, ADHD-unaffected=9) with the protective haplotype,
and 8 individuals (all unaffected) with haplotype variants differing from the susceptibility and protective 
haplotype variants. Across all individuals carrying the haplotype with susceptibility variants, NAA/Cr 
was significantly decreased in the left lateral thalamus (P<0.01), left medial thalamus (P<0.05), and the 
right striatum (p<0.05), and significantly increased in the inferior-posterior cerebellar vermis49 (p<0.05).
To control for ADHD status, we examined the effect of the number of copies of haplotypes containing 
susceptibility and protective variants on the NAA/Cr ratio. The NAA/Cr ratio increased monotonically 
in the right medial and lateral thalamus in relation to the number of copies of the susceptibility 
haplotype (Figure 4B). Carriers of two copies of the susceptibility haplotype had the lowest levels of 
NAA/Cr; the ratio increased in a dosage-dependent fashion, reaching the highest levels in individuals 
with two copies of the protective haplotype and in controls, i.e. those individuals with variants different 
from the susceptibility and protective haplotypes (p<0.05). 
Response to Stimulant Medication
ADHD individuals belonging to clusters 2, 4, 6 and 7 in figure 5A were defined as responders to 
stimulant treatment. No significant difference was found between responders and non-responders for 
demographic or clinical variables such as sex, age, ADHD subtype, and type of stimulant medication 
used for the treatment of ADHD symptoms (Table 6, supplementary information). Significant 
association, both at the marker (p<0.05) and haplotype (p<0.01) level, was for response to stimulant 
medication and SNP marker rs6551665 (which was also associated with ADHD)(Figure 5B and 5C). 
Because we wanted to control for a possible confounder effect of the LPHN3 associated SNPs to ADHD 
in any pharmacogenetic protocol we designed an experiment looking for association between genotype 
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and baseline SWAN scores in order to dissect any effect correlated with specific symptom dimensions 
of ADHD. Thus far, A Quantity  quantifying the change in the SWAN scale was defined as follows:
For the question i and the individual j we calculated:
01,2,...,24,18,...,2,1       ,,,,,  jiQQ OFFjiONjiji
Which compares SWAN scale scores for all the questions in each individual when they were ON vs. 
OFF medication. Given ji, we performed a Likelihood Ratio Test (LRT) between two models: Model 
1: GenotypeAgeSex  ~ , where Genotype refers to G/G, G/A, and A/A of  rs6551665, being A/A
the reference genotype for comparisons, and Model 2:  AgeSex  ~ . The LRT disclose a significant 
improvement of the model while including the genotype variable (data not presented). In order to 
determine the significance and direction of the Genotype effect, an ANOVA for Model 1 was 
conducted. Significant positive Genotype effects were identified for questions 2, 3 and 9 of the 
Inattention component (Q2: F(2, 160) = 7.16, P = 0.008093; Q3: F(2, 160) = 5.85, P = 0.01487; Q9: F(2,160) =
4.80, P = 0.009424) as well as for question number 18 of the H/I component (Q18: F(2,160) = 3.53, P =
0.03167). We concluded that genotypes having either one or two copies of the G allele had a positive 
effect on 
A similar approach was used to quantify the Genotype effect on both the Inattention and 
Hyperactivity/Impulsivity (H/I) dimensions of the SWAN scale. A Likelihood Ratio Test (LRT) 
between two models: Model 1:  GenotypeAgeSexnInattentio  ~
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Model 2:  AgeSexnInattentio  ~ , where OFFnInattentioONnInattentionInattentio SS ,,  , with ONnInattentioS , and 
OFFnInattentioS , are, respectively, the sum the SWAN scores for the Inattention questions (questions 1-9) ON 
and OFF medication. Analogously, we performed an LRT test to compare models with the same 
structure as above but using OFFIHONIHIH SS ,/,//  . Here, ONIHS ,/ and OFFIHS ,/ are, respectively, the 
sum of the SWAN scores for the H/I questions (questions 10-18). Significant positive Genotype effects 
were identified for the Inattention dimension (F(2, 159) = 3.71, P = 0.02646) but for the H/I dimension 
(F(2, 159) = 2.41, P = 0.09726).
Discussion
The research program that was initiated in 200250and produced intermediate results soon after14was 
successful in locating and characterizing a novel gene that contributes to the genetic etiology of ADHD.  
The unbiased linkage scan identified an ADHD susceptibility region on chromosome 451, 52.  Here we 
provide the results of fine mapping that narrowed the region to coding sequence of LPHN3 (exons 4 
through 19) that contains important functional domains and most of the splice isoform variability of the 
gene.
Iterative and expanded analyses of multiple generations of ADHD families from a genetic isolate 
in Colombia provided a consistent and reliable presence of association and linkage at the marker and 
haplotype level of LPHN3 variants.  Association with ADHD was replicated in US, German and 
Spanish families and in a case-control analysis of a Norwegian sample.
The effect was larger in the Paisa sample than in the samples used for replication. This may reflect 
the unique characteristic of the Paise isolate or the method of ascertainment of the sample, which was 
from families with a high prevalence of ADHD (about 30%) and a subtype with comorbidity with 
conduct disorder and substance use16, 53.  The replicated association suggests that regulation of LPHN3
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expression may be involved in the pathogenesis of ADHD. LPHN3 is a member of the LPHN subfamily 
of G-protein coupled receptors (GPCRs). LPHNs have seven transmembrane regions as well as long N-
terminal extracellular sequences containing a 19-amino acid signal peptide (GPCR proteolytic site, GPS 
domain), and a serine/threonine-rich glycosylation region54 (Figure 1D). LPHN1 and LPHN2 serve as 
receptors for -latrotoxin, a component of the venom of the black widow spider (latrodectus mactans); 
-latrotoxin interacts with neuronal GPCRs to stimulate exocytosis of GABA-containing presynaptic 
vesicles55. LPHN3 is the most brain-specific LPHN54, 56; in fact, other GPCRs, such as DRD4 and 
DRD5, have been associated directly with ADHD57.
The association of LPHN3 with increased risk (OR~= 1.2) points to new neuro-molecular 
mechanisms related to ADHD. That increased risk appears consonant with the role of LPHN3 in 
neuronal transmission and maintenance of neuron viability. In fact, the dosage of the LPHN3
susceptibility haplotype varied inversely with the ratio of NAA/Cr, a measure of neuronal number 
known to be abnormal in ADHD. Moreover, mice lacking the closely related LPHN1, although viable 
and fertile, attend poorly to their offspring, resulting in increased neonatal mortality58.
The interpretation of the 1.2 OR figure must be placed in the context of its potential impact for 
the clinical and epidemiological practice when dealing with ADHD in the general population. We think 
that the Population Attributable Risk (PAR), as a measure of epidemiological impact, can provide a 
figure at glance about the consequences (prevalence and outcome) of an association between an 
exposure factor (LPHN3 common variant conferring susceptibility) and a disease (ADHD) at the 
population level 59-61. Specifically, the PAR defines the proportion of ADHD cases that could be treated 
if it were possible to control for the effects of the LPHN3 common variant conferring susceptibility to 
ADHD.The PAR is a function of the relative risk (RR) and the probability of exposure (Pe) given that a 
person has the disease. Because of family-based samples provide OR instead of RR, and for a highly 
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prevalent disorder, as ADHD, the OR is not a good estimator of RR, we calculated PAR% for marker 
rs65511665 with the case-control-based sample from Norway, as proposed by Hildebrandt et al.62. The 
95% confidence intervals were estimated as Bz 2ˆ2/1 ˆˆ  	 
 where ˆ is the PAR% point estimation, 
2/1 z is the 2/1  quantile of the standard normal distribution, and B
2
ˆˆ	 is the simulation-based
variance of ˆ given that B random samples are drawn. To approach this variance, a total of B=100,000 
samples were generated from a multinomial distribution as proposed elsewhere 59, 60. Thus far, the 
PAR% for the marker rs6551665 in the Norway sample is 8.99 (95% CI= 6.69-11.28) meaning that by 
controlling the effect of the LPHN3 common variant conferring susceptibility to ADHD, a reduction of 
~9% in the ADHD incidence in the Norway population would be observed. Though this figure is very 
encouraging, we anticipate that several additional population-based epidemiological studies would be 
needed as well as clinical and pharmacogenetic trials in order to find specific ways of reduce the effect 
of this exposure factor. 
The spatial and temporal expression of LPHN3 also supports its role in the pathogenesis of 
ADHD. LPHN3 is expressed in regions of the brain implicated in ADHD (i.e., the amygdala, caudate 
nucleus, pontine nucleus, and cerebellar Purkinje cells48) and at earlier ages in human post-mortem 
brains63 (i.e., at a time in brain development when ADHD is considered to emerge48). 
It is very intriguing that the same variant (SNP marker rs6551665) associated with susceptibility 
to ADHD is also associated with response to stimulant medication. This opens a window for the 
evaluation of molecular substrates of ADHD and development of new drugs targeting new genes and 
brain pathways involved in ADHD.
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Figure Legends
Figure 1.
A. Results for association and linkage disequilibrium analyses on extended and nuclear ADHD 
families of the Paisa community (Antioquia, Colombia). On the x-axis are base pair coordinates 
(60-80 Mb) at 4q13.2; on the y-axis, -log (p). Dots represent the distribution of the Z statistic 
(single marker-based) for extended families: Black dots represent nuclear families; Red dots, the 
pooled families. The continuous lines of different colors represent the distribution of absolute 
values for -log (p) after testing for linkage disequilibrium using a permutation test on haplotype 
windows of different sizes. This level of significance was robust with respect to different 
haplotype windows (from 3 to 7 markers) and to correct for multiple comparisons. The 
Bonferroni-adjusted threshold p value is represented as a red line at -log(p) = 4.25. A significant 
peak of association is located at the region between coordinates 62 Mb and 63 Mb. 
B. Annotated structure of LPHN3 showing exons 1-24, the major protein structural domains, and 
the area of the susceptibility haplotype. The haplotype (in red) covers the olfactomedin domain, 
part of the mucin-like stalk, the hormone receptor (HR) domain, the G-Protein Coupled Receptor 
(GPCR) Proteolytic Site – (GPS) domain, and transmembrane helices 1-6 of the seven 
transmembrane spanning region. The isoforms represent the three splice site variants of LPHN3. 
C. Haplotype variants transmitted in affected individuals from families with significant linkage 
of ADHD to 4q13.2. Comparison of these variants is carried out against F9 (row 1), the family 
providing the most to the linkage signal as published in Arcos-Burgos et al 14. The shared region 
in orange exactly corresponds to the region mapped by family-based genetic association 
analyses.
D. Structure of LPHN3 with the protein domains that correlate with the ADHD susceptibility 
haplotype in red.
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Figure 2.
A. Location at the LPHN3 gene of the three markers i.e. rs6551665, rs1947274, and rs2345039
reaching significance at the meta-analysis after 10000 permutations.
B. Forest plot of odds ratio showing fixed effects results for rs6551665 (OR =1.23, 95% CI 
1.09-1.137, p=3.46x10-4), rs1947274 (OR =1.23, 95% CI 1.09-1.38, p=5.41x10-4), and 
rs2345039 (OR =1.21, 95% CI 1.08-1.35, p=8.97 x10-4), through populations.
Figure 3.
A. Northern blots reveal expression of LPHN3 mRNA in different regions of the human brain. 
Lane 1, Amygdala; Lane 2, Caudate Nucleus; Lane 3, Corpus Callosum; Lane 4, Hippocampus; 
Lane 5, Whole Brain Extract; Lane 6, Thalamus; Lane 7, Cerebellum; Lane 8, Cerebral Cortex; 
Lane 9, Medulla; Lane 10, Spinal Cord; Lane 11, Occipital Pole; Lane 12, Frontal Lobe; Lane 
13, Temporal Lobe; and Lane 14, Putamen.
B. In situ hybridization of human brain tissue from a 2-year old reveals positive cytoplasmic 
signal with LPHN3 antisense. LPHN3 sense provided a negative control. Selected positive
neurons are marked by arrows. a,b, Amygdala; c,d, Caudate Nucleus; e,f, Pontine Nuclei; g,h, 
Cerebellum 
C. Immunohistochemistry of human brain tissue from a 2-year old reveals positive cytoplasmic 
immunoreactivity with LPHN3 antibody. Primary LPHN3 antibody was omitted for negative 
control. Selected positive neurons are marked by arrows. a,b, Amygdala; c,d, Caudate Nucleus; 
e,f, Pontine Nucleus; g,h, Cerebellum. Immunoreactive Purkinje cells are marked by arrows.
Figure 4
A. 1H-MRS brain imaging. Turquoise squares show voxel selection at different brain structures 
for which 1H-MRS ratios were acquired. a, right and left striatum (3-4 voxels); b, right and left 
lateral (2 voxels, blue) and medial (2 voxels) thalamus; c and d, right and left anterior (1 voxel)
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and posterior (1 voxel) cingulate gyrus; e, right and left mid-cingulate gyrus (1 voxel); f and g, 
posterior-inferior vermis (2 voxels).
B. Plots of marginal means for levels of NAA/Cr at the right medial and lateral thalamus (y-
axis), showing an inverse relationship between the NAA/Cr ratio and the number of copies of the 
the haplotype carrying variants of susceptibility of the markers rs6551665, rs1947274, and 
rs2345039. On the x-axis are points for 2S (two copies of the susceptibility haplotype), 1S (one 
copy of the susceptibility haplotype), 1P (one copy of the protective haplotype), 2P (two copies 
of the protective haplotype), and controls (no copies of either haplotype). Adjacent to the plot is 
the GLM incorporating the effects of sex, haplotype carrier status, affection status, and age.
Figure 5
A. Profile plot of clusters derived from latent class cluster analyses (LCCA) applied to symptoms 
obtained by the SWAN Scale for ADHD Symptoms Screened while being OFF and ON 
medication. Attention Deficit (Inattention) items abbreviated for caption OFF medication (q1-
q9): q1-careless, inattentive, q2-sustains attention poorly, q3-appears to not listen, q4-poor 
follow through, q5-disorganized, q6-avoids/dislikes sustained mental effort, q7-loses needed 
objects, q8-easily distracted, and q9-often forgetful. Hyperactivity/Impulsivity items (q10-q18): 
q10-fidgets or squirms, q11-can’t stay seated, q12-restless, q13-loud, noisy, q14-always “on the 
go”, q15-talks excessively, q16-blurts out, q178-impatient, and q18-intrusive. Similar sequence 
is followed for items while being ON medication, e.g. (q1_med-q18_med). Age categories and 
sex are also presented. Clusters 2, 4, 6 and 7 were defined as those where the stimulant treatment 
was effective.
B. Marker and haplotype wise association analyses of variants associated to ADHD 
susceptibility to stimulant medication response.
C. LD block containing the SNP rs6551665 and two additional surrogate markers, rs1947275 
and rs9683662: OT: over transmitted, T: Transmitted, U: no-transmitted.
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Table 1. Summary of the features of the different population samples where this study was performed
Sample Type of 
study
Total 
Number of 
Ascertained 
Families
Number of 
Individuals 
with ADHD
Number of 
Unaffected 
Individuals
Number of 
Individuals 
with 
Undefined 
Phenotype
Total 
Number of 
Individuals
Clinical Assessment 
and Instruments Used 
for ADHD 
Phenotyping
Reference
Original set of 
Multigenerational 
and Extended Paisa 
Families*
Family-
Based
18 142 264 27 433 -Structured diagnostic 
interview
-DICA-IV-P
5
Additional set of 
Nuclear Paisa 
Families for second 
stage analysis
Family-
Based
137 214 222 91 527 -Structured diagnostic 
interview
-DICA-IV-P
5
US1 Family-
Based
316 630 647 88 1365 -Structured diagnostic 
interview
-Vanderbilt, -SWAN, 
and -DICA-IV-P
17
US2 Family-
Based
322 356 644 0 1000 -Structured diagnostic 
interview
-Vanderbilt, -SWAN, 
and -DICA-IV-P
18
German Families Family-
Based
231 406 40 516 962 -Structured
diagnostic interview I, 
II, WURS, CAARS, K-
SADS-PL, CBCL
19
Norway Case-
Control
0 450 585 0 1035 -Structured diagnostic 
interview. ASRS, 
WURS
52
Spain Family-
Based
386 429 129 480 1038 -Structured
diagnostic interview (K-
SADS-PL)- Conners’ 
Parent  and Teacher 
Rating Scale: (CPRS-R: 
L, CTRS-R:L)
21, 53
Total 1410 2627 2531 1202 6360
*58 additional individuals were sampled for families exhibiting linkage to 4q13.2 from the originally 375 reported.14
Table 2. Meta-analysis results for three significant markers after correction by multiple comparisons
Population Single Nucleotide Polymorphism  ( [ T:UT ] / OR / 95%CI /
Weight )
rs6551665 [G:A] rs1947274 [C:A] rs2345039 [C:G]
PAISA [ 45:22 ] / 2.0454 / 1.2283 - 3.4054 /
14.7761
[ 33:19 ] / 1.7368 / 0.9876 - 3.0538 /
12.0576
[ 41:27 ] / 1.5185 / 0.9342 - 2.4680 /
16.2794
US1 [ 98:63 ] / 1.5555 / 1.1335 - 2.1345 /
38.3478
[ 89:61 ] / 1.4590 / 1.0533 - 2.0207 /
36.1933
[ 99:72 ] / 1.375 / 1.0149 - 1.8625 /
41.6842
US2 [ 151:134 ] / 1.1268 / 0.8930 - 1.4219 /
70.9964
[ 127:113 ] / 1.1238 / 0.8722 - 1.4480 /
59.7958
[ 148:127 ] / 1.1653 / 0.9193 - 1.4770 /
68.3490
GERMANY [ 96:84 ] / 1.1428 / 0.8527 - 1.5316 /
44.8
[ 89:78 ] / 1.1410 / 0.8419 - 1.5463 /
41.5688
[ 88:77 ] / 1.1428 / 0.8417 - 1.5516 /
41.0666
NORWAY* [ 271/397:245/433 ]
/ 1.2064 / 0.9681 - 1.5032 /
79.3648
[ 281/397:253/431 ] / 1.2057/
0.9697 - 1.4991 /
80.9692
[ 311/391:283/431 ]/
1.2113 / 0.9805 - 1.4963 /
86.0086
SPAIN [ 127:115 ] / 1.1043 / 0.8581 - 1.4212 /
60.3512
[ 120:99 ] / 1.2121 / 0.9289 - 1.5816 /
54.2465
[ 109:98 ] / 1.1122 / 0.8466 - 1.4610 /
51.6038
Fixed-Effects 
Meta-analysis
(OR / 95%CI / 
p-value)
1.2258 / 1.0964 - 1.3705 / 3.46E-4 1.2275 / 1.0929 - 1.3786 / 5.41E-4 1.2094 / 1.0810 - 1.3530 / 8.97E-4
*Case-Control data

